Advertisement
Advertisement
ARDX
Ardelyx, Inc.
6.35
USDSponsored
+0.08
+1.28%
May 21, 15:58 UTC -4
Closed
After-Market
6.34
0.00
-0.08%
ARDX Earnings Reports
Positive Surprise Ratio
ARDX beat 26 of 42 last estimates.
62%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$130.76M
/-$0.03
Implied change from Q1 26 (Revenue/ EPS)
+38.41%
/-80.00%
Implied change from Q2 25 (Revenue/ EPS)
+33.89%
/-62.50%
Ardelyx, Inc. earnings per share and revenue
On Apr 30, 2026, ARDX reported earnings of -0.15 USD per share (EPS) for Q1 26, missing the estimate of -0.14 USD, resulting in a -1.42% surprise. Revenue reached 94.47 million, compared to an expected 94.12 million, with a 0.37% difference. The market reacted with a +8.69% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 11 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 130.76 million USD, implying an decrease of -80.00% EPS, and increase of 38.41% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Wellgistics Health, Inc. Common Stock
Report Date
May 19, 2026 For Q1 26
Estimate
-Actual
-$0.07
Surprise
-
Traws Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.75
Actual
-$0.53
Surprise
+29.78%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
AIM ImmunoTech Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.37
Actual
-$0.56
Surprise
-52.53%
FAQ
What were Ardelyx, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Ardelyx, Inc. reported EPS of -$0.15, missing estimates by -1.42%, and revenue of $94.47M, 0.37% above expectations.
How did the market react to Ardelyx, Inc.'s Q1 2026 earnings?
The stock price moved up 8.69%, changed from $6.33 before the earnings release to $6.88 the day after.
When is Ardelyx, Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Ardelyx, Inc.'s next earnings report?
Based on 11
analysts, Ardelyx, Inc. is expected to report EPS of -$0.03 and revenue of $130.76M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement